#Sweden #Stockholm #SciBase #Capital Raise #Rights Issue

SciBase's Strategic Capital Raise

On December 20, 2024, SciBase Holding AB, a forward-thinking medical technology firm specializing in dermatology, announced a substantial capital raise initiative. This move follows the recent approval of a new prospectus by the Swedish Financial Supervisory Authority, marking a pivotal moment for the company as it strives to further its mission in healthcare innovation.

Understanding the Capital Raise

The company disclosed the total capital to be raised amounts to roughly SEK 81.8 million. This comprises two forms of issuance: a directed issue of units and a rights issue, differentiating the scopes of participation for existing and new shareholders. The directed issue is projected to secure around SEK 22.5 million, whereas the rights issue aims to raise approximately SEK 59.3 million. This dual-approach allows existing shareholders preferential rights in acquiring units, trading under the stipulated framework, balancing interests between current investors and new entrants.

Key Components of the Offer

A single unit encapsulates three shares along with three warrants occupying series TO 3, effectively enabling greater flexibility and investment potential for stakeholders. The implementation of these units through the capital raise is a clear demonstration of SciBase's efforts to deepen its financial foundation, thereby facilitating future growth and innovation.

The extraordinary general meeting held on December 13, 2024, played a crucial role in validating the Board of Directors' resolution regarding this capital raise. With such endorsement, the company is positioned uniquely to leverage this financial backing towards mitigating patient health issues through revolutionary technology-driven solutions.

Availability of the Prospectus

The approved prospectus regarding the rights issue, which outlines detailed terms and procedures for participation, is readily accessible through both SciBase and Carnegie's official websites. Interested investors can find this documentation that emphasizes transparency surrounding the offering, reinforcing SciBase's commitment to regulatory compliance and ethical governance.

The timeline for the rights issue is meticulously crafted:

• - December 20, 2024: Record date for participation in the rights issue.
• - December 27 - January 8, 2025: Trading period for unit rights.
• - December 27 - January 13, 2025: Subscription period.
• - January 14, 2025: Expected date for disclosing the outcome of the rights issue.

The Importance of the Capital Raise

This funding effort is particularly significant as SciBase stands at the frontier of dermatological advances, providing unique diagnostic solutions through its Nevisense platform. By integrating artificial intelligence and advanced Electrical Impedance Spectroscopy (EIS), the company enhances diagnostic accuracy, enabling proactive management of skin health while being committed to reducing healthcare costs as well.

As SciBase has been in operation for over 20 years, accumulating extensive research from their base at the Karolinska Institute in Stockholm, the capital raised from this initiative will be pivotal in not only sustaining but also advancing their technological innovations.

Their ongoing trajectory on the Nasdaq First North Growth Market since June 2, 2015, is a testament to their operational success and market trust. As they work alongside Penser by Carnegie and Advokatfirman Schjødt for advisory services, stakeholders can be assured of professional management throughout this process.

This capital raise is not just a financial maneuver; it represents SciBase's commitment to improving patient outcomes and reinforcing its role as a leader in the medical technology space. With every unit issued, SciBase advances towards milestones that echo their mission of proactive medical interventions and patient care enhancement.

To learn more about this exciting phase for SciBase, and to gain insights into how their fundraising strategy will influence future operations, stakeholders are encouraged to explore the detailed prospectus available at their official website.